HUP0301581A2 - Sejteken prezentált peptidek - Google Patents

Sejteken prezentált peptidek

Info

Publication number
HUP0301581A2
HUP0301581A2 HU0301581A HUP0301581A HUP0301581A2 HU P0301581 A2 HUP0301581 A2 HU P0301581A2 HU 0301581 A HU0301581 A HU 0301581A HU P0301581 A HUP0301581 A HU P0301581A HU P0301581 A2 HUP0301581 A2 HU P0301581A2
Authority
HU
Hungary
Prior art keywords
determination
peptides
cells
peptides presented
methods
Prior art date
Application number
HU0301581A
Other languages
English (en)
Inventor
Francis J. Carr
Graham Carter
Koen Hellendoorn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUP0301581A2 publication Critical patent/HUP0301581A2/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A találmány tárgyát eljárások képezik emlős sejtek felszínénprezentált peptidek meghatározására egy fehérjének a sejtekhez történőhozzáadását követően. A találmány tárgyát képezik továbbádiagnosztikai tesztek, amelyek ilyen peptidek meghatározásán vagyilyen peptidek meghatározásából keletkező módosított molekulákmeghatározásán alapulnak, mint például olyan gyógyászati entitásokmeghatározásán, amelyeknek specifikus biológiai aktivitása éscsökkentett vagy fokozott immunogenitása van, összehasonlítva nemmódosított molekulákkal. A találmány szerinti eljárásokat előnyösentömegspektroszkópiás (MS) eszközökkel valósítják meg. Ó
HU0301581A 2000-08-03 2001-07-26 Sejteken prezentált peptidek HUP0301581A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0018901.9A GB0018901D0 (en) 2000-08-03 2000-08-03 Peptides presented by cells
PCT/EP2001/008625 WO2002012899A2 (en) 2000-08-03 2001-07-26 Peptides presented by cells

Publications (1)

Publication Number Publication Date
HUP0301581A2 true HUP0301581A2 (hu) 2003-08-28

Family

ID=9896790

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301581A HUP0301581A2 (hu) 2000-08-03 2001-07-26 Sejteken prezentált peptidek

Country Status (20)

Country Link
US (1) US20030171290A1 (hu)
EP (1) EP1305343B1 (hu)
JP (1) JP2004506202A (hu)
KR (1) KR20030037272A (hu)
CN (1) CN1511164A (hu)
AT (1) ATE306498T1 (hu)
AU (1) AU2001283958A1 (hu)
BR (1) BR0112925A (hu)
CA (1) CA2417767A1 (hu)
CZ (1) CZ2003464A3 (hu)
DE (1) DE60114018T2 (hu)
GB (1) GB0018901D0 (hu)
HU (1) HUP0301581A2 (hu)
MX (1) MXPA03000901A (hu)
NO (1) NO20030495D0 (hu)
PL (1) PL358874A1 (hu)
RU (1) RU2003105806A (hu)
SK (1) SK1982003A3 (hu)
WO (1) WO2002012899A2 (hu)
ZA (1) ZA200301637B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004513332A (ja) * 2000-09-18 2004-04-30 ジェンザイム、コーポレーション 質量分析法（ｍａｌｄｉ−ｔｏｆ）に基づいて抗体標的を同定するための方法
ATE386937T1 (de) * 2001-06-19 2008-03-15 Suntory Ltd Verfahren zur analyse eines in der zelle auftretenden proteins oder einer mit dem protein wechselwirkenden substanz
AU2004281634B2 (en) * 2003-09-03 2011-01-27 Dendritherapeutics, Inc. Multiplex vaccines
BRPI0415457A (pt) 2003-10-16 2006-12-05 Micromet Ag constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
WO2007085266A1 (en) * 2006-01-30 2007-08-02 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US10722562B2 (en) * 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
MX2012005164A (es) 2009-11-05 2012-10-03 Cephalon Australia Pty Ltd Tratamiento de cancer que involucra genes kras o braf mutados.
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
KR102220382B1 (ko) * 2013-05-13 2021-02-25 셀렉티스 면역요법을 위한 매우 활성인 ｔ 세포를 조작하는 방법
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
IL259023B (en) * 2016-09-30 2022-09-01 Cellex Life Sciences Incorporated Preparations containing protein-charged exosomes, methods for their production and uses thereof
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
JP2021503897A (ja) 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド 新生抗原のためのジャンクションエピトープ提示の低減

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258817T3 (es) * 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
EP1051432B1 (en) * 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
AU4676500A (en) * 1999-04-28 2000-11-10 Northwestern University Localization of major peptide autoepitopes for nucleosome specific t cells of systemic lupus erythematosus

Also Published As

Publication number Publication date
SK1982003A3 (en) 2003-08-05
ZA200301637B (en) 2004-02-03
BR0112925A (pt) 2003-08-26
NO20030495L (no) 2003-01-31
CA2417767A1 (en) 2002-02-14
CN1511164A (zh) 2004-07-07
DE60114018D1 (de) 2006-02-23
PL358874A1 (en) 2004-08-23
CZ2003464A3 (cs) 2003-06-18
ATE306498T1 (de) 2005-10-15
KR20030037272A (ko) 2003-05-12
NO20030495D0 (no) 2003-01-31
MXPA03000901A (es) 2003-06-24
DE60114018T2 (de) 2006-06-29
JP2004506202A (ja) 2004-02-26
WO2002012899A2 (en) 2002-02-14
AU2001283958A1 (en) 2002-02-18
EP1305343A2 (en) 2003-05-02
RU2003105806A (ru) 2004-07-20
EP1305343B1 (en) 2005-10-12
US20030171290A1 (en) 2003-09-11
GB0018901D0 (en) 2000-09-20
WO2002012899A3 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
HUP0301581A2 (hu) Sejteken prezentált peptidek
HUP0202532A2 (hu) Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
NO20043245L (no) Bindingsproteiner som biosensorer
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
DK1323728T3 (da) Fremgangsmåde til diagnosticering af Alzheimers sygdom på basis af et genstransskriptionsmönster
NO20043259L (no) Bindingsproteiner som biosensorer
ATE477224T1 (de) Verwendung von miniatursierten vorrichtungen zur herstellung von radiomarkierten verbindungen
ATA14642003A (de) Impfstoff für die alzheimer-krankheit
EP2330127A3 (en) Kallikrein-inhibiting Kunitz Domain proteins and nucleic acids encoding the same
HUP0200400A2 (hu) Fehérjék izolálása és elemzése
AR038568A1 (es) Anticuerpos anti-a beta y su uso
NZ543467A (en) The severe acute respiratory syndrome coronavirus
AU2001294541A1 (en) Mammalian genes; related reagents and methods
HUP0003513A2 (hu) Apoptózist indukáló monoklonális antitest
DE69934688D1 (de) Durch mechanischen stress induzierte gene, deren expressionsprodukte und deren verwendung.
WO2006086561A3 (en) Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
BR0314155A (pt) Métodos para diagnosticar câncer cervical
RS20100249A (en) CONJUGATES AND PROCEDURES FOR THEIR PRODUCTION, AND THEIR USE FOR THE TRANSPORT OF MOLECULES THROUGH BIOLOGICAL MEMBRANE
DE50213290D1 (de) Erfassung von signalen biologischen ursprungs
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
WO2004050870A3 (en) Genetic switches for the detection of fusion proteins

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees